United States In Vitro Toxicity Testing Market to Reach USD 18.2 Billion by 2031, Driven by Advances in Cell Culture Technologies and Regulatory Support | DataM Intelligence

The Global In Vitro Toxicity Testing Market was valued at US$ 10.6 billion in 2024 and is projected to reach US$ 18.2 billion by 2031, growing at a CAGR of 8.1% during the forecast period (2024-2031). Market growth is primarily driven by the increasing demand for alternatives to animal testing, advancements in cell culture technologies, and stringent regulatory frameworks promoting non-animal safety assessment methods.

The market is strategically positioned within the biotechnology and pharmaceutical testing landscape, as in vitro models provide enhanced accuracy, reproducibility, and ethical compliance in toxicity evaluation. Continuous innovation in organ-on-chip systems, 3D cell cultures, and high-throughput screening is further strengthening the adoption of in vitro testing across pharmaceutical, cosmetic, and chemical industries, driving sustained market expansion globally.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/in-vitro-toxicity-testing-market?sai-v

The In Vitro Toxicity Testing Market involves laboratory techniques that evaluate the safety and potential toxic effects of chemicals, drugs, and cosmetics on cultured cells, reducing the need for animal testing.

Key Developments

✅ October 2025 (United States): U.S. biotechnology companies introduced next-generation in vitro 3D cell culture models designed to replicate human organ microenvironments for more accurate toxicity assessments. These models are improving drug safety profiling while reducing reliance on animal testing.

✅ August 2025 (Japan): Japanese research institutions unveiled advanced stem cell-based toxicity testing kits, enabling early detection of neurotoxicity and hepatotoxicity in pharmaceuticals. The technology supports personalized toxicology research and aligns with Japan's commitment to ethical testing practices.

✅ June 2025 (United States): A major U.S.-based biotech firm launched an AI-enabled toxicity prediction platform that integrates machine learning with in vitro assay data to enhance chemical risk assessment and shorten drug discovery timelines.

Mergers & Acquisitions

✅ September 2025 (United States): Thermo Fisher Scientific Inc. acquired a niche U.S. startup specializing in organ-on-chip systems to expand its non-animal toxicology testing portfolio and strengthen its foothold in preclinical safety research.

✅ May 2025 (Japan): A leading Japanese diagnostics company entered a strategic partnership with a European toxicology lab to co-develop human cell-based toxicity screening solutions aimed at enhancing global regulatory compliance and market access.

Market Outlook

The In Vitro Toxicity Testing Market is projected to experience robust growth through 2031, driven by increasing regulatory support for non-animal testing, advancements in 3D cell culture and organ-on-chip technologies, and the integration of AI-driven predictive analytics. The United States leads in AI and high-throughput screening adoption, while Japan continues to advance with stem cell-based and microfluidic testing systems. The global shift toward ethical, efficient, and cost-effective toxicology testing positions this market for strong expansion in the coming years.

Key Players:

Abbott Laboratories | Agilent Technologies | Bio-Rad Laboratories | Covance | Eurofins Scientific | GE Healthcare | Merck KGaA | Promega Corporation | Quest Diagnostics | Thermo Fisher Scientific

Key Highlights:

• Abbott Laboratories - Reported revenue of approximately USD 41 billion in 2024, with strong growth in diagnostic testing and development of advanced in-vitro assay technologies for toxicology applications.
• Agilent Technologies - Generated around USD 6.8 billion, leading in analytical instrumentation and cell analysis systems used for chemical safety and toxicology testing.
• Bio-Rad Laboratories - Achieved revenue of about USD 3.9 billion, focusing on life science research and providing key reagents and instruments for in-vitro toxicity studies.
• Covance (Labcorp Drug Development) - Reported over USD 5 billion in revenue, offering comprehensive preclinical and in-vitro toxicity testing services to pharmaceutical and biotechnology companies.
• Eurofins Scientific - Generated approximately USD 7.5 billion, expanding its in-vitro testing capabilities for environmental, chemical, and pharmaceutical toxicity assessment.
• GE Healthcare - Achieved around USD 18 billion in 2024, advancing in-vitro imaging and cell-based testing technologies for predictive toxicology.
• Merck KGaA - Reported revenue of USD 24 billion, investing in innovative in-vitro models and reagents supporting chemical and drug safety evaluations.
• Promega Corporation - Generated around USD 900 million, known for its bioluminescent cell-based assays used extensively in cytotoxicity and genotoxicity testing.
• Quest Diagnostics - Reported USD 10 billion in 2024, expanding its laboratory testing services to include advanced toxicology and safety screening platforms.
• Thermo Fisher Scientific - Achieved revenue of USD 43 billion, dominating the market with high-throughput in-vitro testing instruments, reagents, and data analytics solutions for life sciences and pharmaceuticals.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=in-vitro-toxicity-testing-market?sai-v
(Purchase 2 or more reports and get 50% discount.)

Market Drivers & Growth:

The growing emphasis on reducing animal testing and adopting alternative testing methods is driving the growth of the in vitro toxicity testing market. This approach allows researchers to assess chemical, cosmetic, and pharmaceutical safety using cell-based assays and tissue cultures instead of animal models.

Increasing regulatory support from organizations such as the FDA, OECD, and the European Commission for non-animal testing methods is further accelerating market expansion.

Rising investments in drug discovery, cosmetics safety testing, and environmental toxicity studies are fueling demand for in vitro testing technologies that offer faster, more reliable, and cost-effective results.

Advancements in cell culture techniques, 3D tissue models, and high-throughput screening systems are improving the accuracy and predictive value of in vitro toxicity assessments.

The global in vitro toxicity testing market is expected to experience steady growth in the coming years, supported by technological innovation, ethical considerations, and regulatory shifts toward alternative testing methods.

Regional Insights:

United States: Dominates the market due to strong pharmaceutical and biotechnology sectors, supportive regulatory policies for alternative testing, and extensive R&D investments in cell-based assays.

Japan: Shows consistent growth driven by increasing adoption of in vitro testing in the cosmetic and chemical industries and a strong focus on technological advancements in life sciences.

Europe: Holds a major share supported by strict regulations against animal testing, strong funding for alternative testing research, and the presence of key industry players and testing laboratories.

Asia-Pacific (Excluding Japan): Expected to witness rapid growth due to expanding pharmaceutical manufacturing, growing awareness of ethical testing standards, and rising government initiatives supporting in vitro research in countries like China and India.

Key Segments:

➥ By Product & Service:
Consumables, Equipment, Assay, Software, Services
Consumables dominate the market due to their recurring demand in toxicity assays and cell-based testing, while Services are rapidly expanding with the outsourcing of toxicity evaluation.
Market Attractiveness: Consumables - High, Services - High, Equipment - Moderate.

➥ By Toxicity Endpoint & Test:
Genotoxicity Testing, Skin Irritation, Corrosion & Sensitization Testing, Cytotoxicity Testing, Ocular Toxicity Testing, Organ Toxicity Testing, Others
Cytotoxicity Testing leads due to its critical role in early-stage drug screening, while Skin Irritation and Sensitization Testing see strong growth driven by cosmetic safety regulations.
Market Attractiveness: Cytotoxicity - High, Skin Irritation & Sensitization - High, Genotoxicity - Moderate.

➥ By Technology:
Toxicogenomics, Cell Culture Technologies, High-Throughput Technologies
Cell Culture Technologies dominate the market as the backbone of in-vitro testing models, while High-Throughput Technologies are rapidly emerging for efficient and automated screening.
Market Attractiveness: Cell Culture - High, High-Throughput - High, Toxicogenomics - Moderate.

➥ By Industry:
Pharmaceuticals & Biopharmaceuticals, Cosmetics & Household Products, Food, Chemicals
Pharmaceuticals & Biopharmaceuticals lead the market with rising demand for predictive safety testing in drug development. Cosmetics & Household Products are growing fast due to bans on animal testing and regulatory shifts toward alternative methods.
Market Attractiveness: Pharmaceuticals & Biopharmaceuticals - High, Cosmetics & Household Products - High, Chemicals - Moderate.

Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/in-vitro-toxicity-testing-market?sai-v

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.